Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

Benefits of Goal-Directed Therapy in Heart Failure

Introduction to Heart Failure Therapies

  • The American College of Cardiology recommends ACE inhibitors or ARBs as foundational first-line therapies for heart failure with reduced ejection fraction (HFrEF), reducing all-cause mortality by 17% 1
  • ACE inhibitors/ARBs decrease all-cause mortality with a number needed to treat (NNT) of 22 over 42 months, which standardizes to an NNT of 26 over 36 months 1

ACE Inhibitors and ARBs

  • ACE inhibitors reduce hospital admissions by 99 per 1000 patient-years of treatment 2
  • ACE inhibitors improve NYHA functional class and quality of life in patients with symptomatic heart failure 2
  • ACE inhibitors delay or prevent the development of symptomatic heart failure in patients with asymptomatic left ventricular systolic dysfunction 2
  • In patients with systolic dysfunction after acute myocardial infarction, ACE inhibitors significantly increase survival 2

Beta-Blockers

  • Beta-blockers provide the most robust mortality benefit among heart failure medications, reducing all-cause mortality by 34% with an NNT of only 9 over 36 months 1
  • Beta-blockers achieve a consistent 30% reduction in mortality across multiple trials 3, 4
  • Beta-blockers reduce hospitalizations by 40% in patients with NYHA class II and III heart failure, translating to 65 fewer hospital admissions per 1000 patient-years 3, 2
  • Beta-blockers improve NYHA functional class and quality of life in heart failure patients 3
  • Bisoprolol, carvedilol, and metoprolol succinate are the evidence-based beta-blockers with proven efficacy in HFrEF 1

Mineralocorticoid Receptor Antagonists (MRAs)

  • MRAs reduce all-cause mortality by 30% with an NNT of only 6 over 36 months, representing one of the most potent mortality benefits in heart failure therapy 1
  • MRAs (spironolactone or eplerenone) reduce the risk of cardiovascular death by 30%, with particularly strong effects on sudden cardiac death 2
  • MRAs reduce hospital admissions by 138 per 1000 patient-years, the highest reduction among all heart failure medications 2
  • Spironolactone is particularly beneficial in HFmrEF patients with poorly controlled hypertension 5, 6

SGLT2 Inhibitors

  • SGLT2 inhibitors reduce all-cause mortality by 17% and hospitalization for heart failure by 27-39%, with benefits occurring within weeks of initiation regardless of diabetes status 1, 8
  • SGLT2 inhibitors reduce the composite endpoint of cardiovascular death or heart failure hospitalization by 21-26%, driven primarily by a 29% reduction in heart failure hospitalizations 5, 6, 8
  • SGLT2 inhibitors decrease the slope of eGFR decline and reduce the risk of chronic kidney disease progression 5, 6, 8
  • Dapagliflozin 10 mg daily and empagliflozin 10 mg daily are the recommended SGLT2 inhibitors with proven mortality and hospitalization benefits 7

Comprehensive Quadruple Therapy Benefits

  • Comprehensive quadruple therapy (ARNI/ACE inhibitor + beta-blocker + MRA + SGLT2 inhibitor) reduces the risk of death by 73% over 2 years compared to no treatment 10
  • Transitioning a 55-year-old patient from traditional dual therapy (ACE inhibitor and beta-blocker) to quadruple therapy extends life expectancy by approximately 6 years 10

REFERENCES

7

Dapagliflozin Use in Non-Diabetic Patients with HFrEF or CKD [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

8

Heart Failure with Reduced Ejection Fraction (HFrEF) Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025